Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State

NCT02608034 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02608034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02608034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 26, 2016
Completion date
September 10, 2018
Enrollment
32 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, braf v600 mutation positive